About CryofocusABOUT CRYOFOCUS

Established in 2013, Cryofocus Medtech (Shanghai) Co., Ltd.，formerly known as Cryofocus Medtech (Shanghai) Company Limited，is a leading medical device company with particular strengths in the field of minimally-invasive interventional cryotherapy. Leveraging our unique liquid nitrogen cryoablation technology, we have developed a comprehensive product portfolio mainly focusing on two therapeutic areas: (i) vascular intervention for the treatment of atrial fibrillation, hypertension and other serious cardiovascular diseases, and (ii) natural orifice transluminal endoscopic surgery, or NOTES, for the treatment of respiratory, urinary, and digestive diseases such as asthma, chronic obstructive pulmonary disease, airway stenosis, bladder cancer, gastric cancer and esophageal cancer.

The core members of the Company have more than 10 years of R&D and engineering experience in medical device related products. Carrying out in-depth research in cryoablation technology.

So far, the Company has successfully developed a number of innovative cryoablation products, committed to making advanced cryoablation technology to benefit a large population of patients.

About Us
Striving to become a global leader in cryotherapy technology in vascular intervention and NOTES

Established in 2013, Cryofocus Medtech (Shanghai) Co., Ltd. is a leading medical device company with particular strengths in the field of minimally-invasive interventional cryotherapy.

Know more

HISTORY

Specialize in development of cryotherapy technology with a goal to becoming a leading platform-based company

2013

  • The Company was established

2015

  • The world first cryoablation treatment for hypertension

    Type test and animal study of the cryotherapy system for bladder cancer completed

2016

  • The cryotherapy system for bladder cancer approved as an “Innovative Medical Device” by NMPA

2017

  • The cryoablation system for hypertension approved as an “Innovative Medical Device” by NMPA

    Multi-center clinical trial of the cryotherapy system for bladder cancer commenced

    The laparoscopic single port multi-channel access platform commercialized

2018

  • Feasibility clinical trial of the cryoablation system for hypertension completed

    Animal study of the cryoablation system for atrial fibrillation completed

    Premarket clinical trial of anti-gastroesophageal reflux system commenced

2019

  • The cryoablation system for atrial fibrillation approved as an “Innovative Medical Device” by NMPA

    The pulmonary nodule localization needle commercialized

    The novel endoscopic clips for anastomosis approved as an “Innovative Medical Device” by Zhejiang Provincial Bureau of NMPA

2020

  • Strategic acquisition of Ningbo SensCure

    Various clinical trials of the cryotherapy applied in respiratory intervention field commenced

2021

  • Regulatory approval application of the cryotherapy system for bladder cancer submitted to NMPA

    Premarket clinical trial of endoscopic clip for anastomosis completed

    Regulatory approval application of the endoscopic clip for anastomosis submitted to NMPA

2022

  • Bladder Cryoablation System approved by NMPA

    Endoscopic anastomosis clip approved by NMPA

2023

  • Asthma Cryoablation Systementered into the confirmatory clinical trial phase

    COPD Cryospray System entered into the confirmatory clinical trial phase

    Submitted the registration application for our Cryoadhesion System

2013
2015
2016
2017
2018
2019
2020
2021
2022
2023

LEADERSHIP TEAM

Extensive experience in R&D and clinical application

We have a strong R&D team, which is led by seasoned veterans with global vision and vast industry experience, and closely collaborates with key opinion leaders (KOLs) in vascular intervention and NOTES to address significant unmet clinical needs.

Years of experience in operation and management of minimally-invasive therapeutic products

The management team has years of experience in operation and management of minimally-invasive vascular intervention and natural orifice transluminal endoscopic surgery (NOTES)
In-depth cryotherapy technology

We have developed cryotherapy technology by ourselves, and successfully developed several international and domestic innovative cryoablation products.

CULTURE

  • Vision

    Build a world-leading platform for minimally-invasive cryotherapy

  • Mission

    Specialize in development of cryoablation technology with commitment to research and
    development of innovative life science technology in China

  • Values

    Focus, precision, integration and innovation

    ★专注（Focus）：专注创新冷冻微创治疗技术。
    ★精准（Precision）：精准医疗以有效、安全、经济的创新技术，让患者最大化获益。
    ★融合(Integration)：融合发展，跨科技领域融合、产学融合等。
    ★创新(Innovation)：不断创新冷冻消融技术，更多创新临床应用。

AWARDS AND HONORS

Drag to move